Evidence map›Paper›PMID 32350057›Full record

ArticleMolecular cancer research : MCR2020

Signals from the Metastatic Niche Regulate Early and Advanced Ovarian Cancer Metastasis through miR-4454 Downregulation.

Subramanyam Dasari, Taruni Pandhiri, Tommaso Grassi, Daniel W Visscher, Francesco Multinu, Komal Agarwal, Andrea Mariani, Viji Shridhar, Anirban K Mitra

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Duality of Collagens in Metastases of Solid Tumors.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Subramanyam DasariMedical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana.
Taruni PandhiriMedical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana.
Tommaso GrassiDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-9404-0596
Daniel W VisscherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Francesco MultinuDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-8535-4059
Komal AgarwalMedical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana.ORCID 0000-0002-7282-7184
Andrea MarianiDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota.
Viji ShridharDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Anirban K MitraMedical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana. anmitra@indiana.edu.
Mayo Clinic · USIndiana University Bloomington · USIndiana University Health · USSt Vincent Hospital · US

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
NCI NIH HHS P50 CA136393
6 · The paper itself

Abstract

Treatment of ovarian cancer is limited by extensive metastasis and yet it remains poorly understood. We have studied the critical step of metastatic colonization in the context of the productive interactions with the metastatic microenvironment with a goal of identifying key regulators. By combining miRNA expression analysis using an organotypic 3D culture model of early ovarian cancer metastasis with that of matched primary and metastatic tumors from 42 patients with ovarian cancer, we identified miR-4454 as a key regulator of both early colonization and advanced metastasis in patients with ovarian cancer. miR-4454 was downregulated in the metastasizing ovarian cancer cells through paracrine signals from microenvironmental fibroblasts, which promoted migration, invasion, proliferation, and clonogenic growth in ovarian cancer cells as well as their ability to penetrate through the outer layers of the omentum. Stable overexpression of miR-4454 decreased metastasis in ovarian cancer xenografts. Its mechanism of action was through the upregulation of its targets, secreted protein acidic and cysteine rich (SPARC) and BCL2 associated athanogene 5 (BAG5), which activated focal adhesion kinase (FAK) signaling, promoted mutant p53 gain of function by its stabilization, and inhibited apoptosis. Because microenvironment-induced downregulation of miR-4454 is essential for early and advanced metastasis, targeting it could be a promising therapeutic approach. IMPLICATIONS: This study identifies a miRNA, miR-4454, which is downregulated by signals from the microenvironment and promotes early and advanced ovarian cancer metastasis through its effects on FAK activation, mutant p53 stabilization, and apoptosis inhibition.

Indexed as

Down-RegulationAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorCell MovementCell ProliferationFemaleFocal Adhesion Kinase 1Gene Expression Regulation, NeoplasticHumansMiceMicroRNAsMutationNeoplasm MetastasisNeoplasm TransplantationOsteonectinAdaptor Proteins, Signal TransducingBAG5 protein, humanFocal Adhesion Kinase 1MicroRNAsMIRN4454 microRNA, humanOsteonectinPTK2 protein, humanSPARC protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID32350057
PMCPMC10788085
OpenAlexW3021510746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.